Clinical efficacy and safety of docetaxel in combination with cisplatin on the platin-sensitive recurrent ovarian cancer in comparison of whole abdominal radiotherapy
To investigate the clinical efficacy and safety of docetaxel in combination with cisplatin in comparison of standard methods of in treatment of platin-sensitive ovarian cancer regimens and in addition to radiotherapy for whole abdomen radiotherapy in platin-sensitive recurrent ovarian cancer and the effect on the levels of VEGF and MMP-2.
We recruited a total of 160 platin-sensitive recurrent ovarian cancer patients between April 2017 and April 2020 who were treated in this hospital, and assessed them based on the treatment chemotherapy and radiotherapy regimens to control, the docetaxel+cisplatin, and Whole abdomen radiotherapy groups. Patients in the control group received the co-medication of paclitaxel and carboplatin, while those in the docetaxel+cisplatin group received the docetaxel in combination with cisplatin. Following treatment, we compared the clinical efficacy, levels of vascular endothelial growth factor (VEGF) and MMP-2 and safety of these three methods between two groups.
the total effectiveness rate of the docetaxel+cisplatin group was 69.09%, significantly higher than 16.36% in the control group and 24% in WAR group (P<0.05). Besides, it was found that treatment in the docetaxel+cisplatin group decreased the levels of VEGF and MMP-2 in serum of patients more evidently than those in the control and whole abdomen radiotherapy groups (P<0.05).
docetaxel in combination with cisplatin performs well, with significant decreases in the levels of VEGF and MMP-2 and reliable safety; while there was a high rate of adverse reactions in patients undergoing whole abdomen radiotherapy.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.